AB Science S.A. (AB.PA)
AB Science S.A.
3, avenue George V
Paris 75008
France
33 1 47 20 00 14
https://www.ab-science.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 89
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Alain Moussy MBA | Co-Founder, Chairman, President, CEO, MD & Scientific Director | 596k | N/D | N/D |
| Mr. Laurent Guy MBA | Chief Financial Officer | N/D | N/D | N/D |
| Mr. Christian FASSOTTE | Global Chief Medical Officer | N/D | N/D | N/D |
| Mr. Alexis BERNARD | Head of Veterinary Sales | N/D | N/D | N/D |
| Mr. Harshad KULKARNI | Head of Statistics | N/D | N/D | N/D |
| Dr. Albert Ahn D.V.M. | President of USA Operations | N/D | N/D | N/D |
Descripción
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Gestión corporativa
La calificación ISS Governance QuickScore de AB Science S.A. a partir del 1 de mayo de 2024 es 10. Las puntuaciones principales son Auditoría: 10; Junta: 10; Derechos del accionista: 10; Compensación: 10.
